Charles River Laboratories launches RightSourceSM insourcing service for biotech and pharma companies

New service will enable companies to completely externalize their biologic quality control (QC) testing program to Charles River

WILMINGTON, Mass. Feb. 18, 2014 - As pharma and biotech companies race to bring new biologic and biosimilar therapies to market, they are increasingly turning to experts in biologics testing and manufacturing, like CRO Charles River, to ensure the safety, quality and consistent development of these complex molecules.

On Thursday, February 20, Charles River Laboratories will launch the first new, flexible insourcing/outsourcing option to biotech and pharma companies. The new service, RightSourceSM, will enable companies to completely externalize their quality control (QC) testing program to Charles River.  AfterCharles River and the client identify the best combination of insourcing and outsourcing options, Charles River will be able to completely manage the client's QC testing program, evaluate and select outsourcing vendors where necessary, and provide a dedicated project manager familiar with the technical aspects of the program to oversee all of client's QC activities. 

"Growing demand for services such as RightSourceSM points to the continued challenges biopharmaceutical companies face, as well as the increased reliance on drug development partners like Charles River, particularly in the area of biologics," said Birgit Girshick, Corporate Senior Vice President, Research Models and Global Biopharmaceutical Services, Charles River.

Charles River's partnership with clients through the RightSourceSM program ensures timely and reliable result delivery in a cost-effective manner to clients.  The RightSourceSM program also allows pharma and biotech companies to reduce risk and costs by utilizing their existing state-of-the-art labs and staff, while taking advantage of Charles River's biosafety testing expertise.

About Charles River's Biopharmaceutical Services

With the most comprehensive biologics testing portfolio in the industry, Charles River offers protocols to meet global regulatory requirements. From biosafety testing and impurity detection to potency determination and lot release programs, our team of scientists and project managers ensure that the most appropriate methods are used for a product. To learn more, visit the company website: http://www.criver.com/products-services/biopharmaceutic-services.

About Charles River

Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.